ARWR / Arrowhead Pharma: We Can Afford To Wait For More Proof

Arrowhead is a promising biotech company with a strong platform and pipeline of drugs targeting various diseases. Arrowhead has expanded its focus fro more_horizontal

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q2 2023 Earnings Conference Call May 2, 2023 4:30 PM ET Company Participants Vincent Anzalone - Vice Pr more_horizontal

Arrowhead Pharmaceuticals has released positive interim results from its Phase 1/2 study of its investigational therapeutic ARO-RAGE for inflammatory more_horizontal

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference more_horizontal

Arrowhead Pharmaceuticals recently received a rating upgrade from SVB Financial and a price target that implies a 44% gain up ahead. Arrowhead Pharmac more_horizontal

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the more_horizontal

Arrowhead Pharmaceuticals, Inc. is a company with strong potential. However, it has yet to conclusively prove the worth of any part of its vast pipeli more_horizontal

For many investors, investing in mid-cap stocks is considered to be a safe portfolio diversification strategy because mid-caps can offer better return more_horizontal